Last reviewed: May 23, 2026
Last updated: May 23, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
GLP-1 medication qualifications involve more than a single metric: candidates typically have a BMI of 27+ with weight-related comorbidities or BMI 30+, plus medical conditions like type 2 diabetes or cardiovascular risk factors. Recent clinical guidelines emphasize that eligibility should account for individual metabolic health and treatment goals.
Understanding your qualification profile matters because it shapes which GLP-1 option, dosing approach, and monitoring plan may be right for you. PlexusDx supports precision-wellness decisions by helping you understand both standard clinical criteria and genetic predispositions that may influence how your body responds to peptide-based therapies.
Standard Medical Criteria for GLP-1 Eligibility
FDA-approved GLP-1 medications for weight management require a BMI of 30 kg/m² or a BMI of 27+ with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or sleep apnea. For type 2 diabetes management, eligibility thresholds differ and are often lower regardless of BMI.
Beyond BMI, providers assess fasting glucose, HbA1c, lipid profiles, and blood pressure. These metabolic markers help determine baseline risk and whether GLP-1 therapy aligns with your clinical picture. Cardiovascular history, kidney function, and gastrointestinal health also inform suitability.
Key Medical Markers That Support GLP-1 Qualification Assessment
Your metabolic profile—not just body weight—shapes GLP-1 eligibility decisions. The following markers help your provider evaluate whether GLP-1 therapy fits your clinical needs and risk profile.
| Medical Marker |
Why It Matters for GLP-1 Qualification |
| BMI (kg/m²) |
Primary threshold: ≥30 or ≥27 with comorbidities; indicator of weight-related health risk |
| HbA1c / Fasting Glucose |
Reflects glycemic control; determines if diabetes management is a treatment goal |
| Blood Pressure |
Cardiovascular risk factor; GLP-1s can help reduce BP in eligible candidates |
| Lipid Panel (LDL, HDL, Triglycerides) |
Metabolic marker; influences overall cardiovascular risk assessment
|
| eGFR / Kidney Function |
Safety marker; some GLP-1 formulations require dose adjustment if eGFR is low |
| Gastrointestinal History |
Exclusion or caution factor; history of pancreatitis or GI obstruction may affect eligibility |
Genetic Predispositions That May Inform Personalized Discussions
Genetic variants in GLP-1 receptor pathways, appetite-regulation genes, and metabolic genes may provide context for how your body processes hunger signals and weight regulation. Variants in GLP1R, GIPR, FTO, and MC4R genes reflect natural variation in peptide sensitivity and metabolic predisposition.
PlexusDx's Precision Peptide Genetic Test reveals predispositions in these four key pathways. Understanding whether you carry variants associated with heightened GLP-1 receptor sensitivity or metabolic risk may help support a more informed conversation with your provider about treatment approach and expectations.
Contraindications and Safety Considerations for GLP-1 Therapy
Certain medical conditions exclude candidates from GLP-1 therapy: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, or severe diabetic retinopathy. Pregnant or breastfeeding individuals should not use GLP-1 medications. Providers also assess for active gallbladder disease and kidney impairment.
If you have a history of thyroid problems, stomach paralysis, or chronic kidney disease, your provider will conduct additional evaluation before initiation. Honest disclosure of your full medical and family history ensures your provider can safely determine if GLP-1 therapy is appropriate for you.
How PlexusDx Supports a More Personalized Approach
PlexusDx helps contextualize GLP-1 qualification by combining standard clinical markers with genetic predisposition data. Your Precision Peptide Genetic Test may help provide context around natural variation in GLP-1 and GIPR receptor sensitivity, FTO metabolic risk, and MC4R appetite-control pathways—should be interpreted with a qualified healthcare provider as part of your overall assessment.
The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 variants. These genetic insights do not predict exact medication response but may support a more nuanced conversation about why certain dosing strategies or formulations might align with your biology.
When you meet standard GLP-1 qualifications, adding genetic predisposition context can help your provider personalize your treatment protocol—from initial dosing to adjustment pace to formulation choice (injection vs. oral). This information empowers a more collaborative, evidence-informed decision-making process with your healthcare team.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Semaglutide and Pregnancy: Safety, Evidence & Provider Guidance
Natural GLP-1 Mimics & Genetics: Weight Management Strategy